The ongoing discourse on mifepristone has prompted significant input from former leaders of the FDA and members of the pharmaceutical industry.
A central theme emerging from these discussions is the question of who holds the regulatory power over mifepristone.
This debate highlights the complexities surrounding the governance of medications and the implications for public health.